carmustine and tamoxifen

carmustine has been researched along with tamoxifen in 63 studies

Research

Studies (63)

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (7.94)	18.7374
1990's	32 (50.79)	18.2507
2000's	19 (30.16)	29.6817
2010's	7 (11.11)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Cheson, BD; Ungerleider, RS	1
Buzaid, AC; Murren, J	1
Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE	2
Glover, DJ	1
Basile, M; Bennett, JM; Blumberg, N; Harris, J; Moskowitz, B	1
Doane, LL; Gilewski, TA; Mitchel, B; Ramming, K; Richards, JM; Vogelzang, NJ	1
Richards, JM	1
Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD	1
Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF	1
Del Prete, SA; Forcier, RJ; LeMarbre, P; Maurer, LH; O'Donnell, J	1
Drings, P; Fritze, D; Massner, B; Queisser, W; Voss, I; Westerhausen, M	1
Fiebig, HH; Schmähl, D	1
Feun, LG; Hurley, J; Liebmann, A; Moffat, F; Raub, WA; Richman, SP; Robinson, D; Savaraj, N	1
Atzpodien, J; Chaitchik, S; Duensing, S; Franzke, A; Kirchner, H; Körfer, A; Lopez Hänninen, E; Poliwoda, H; Schomburg, A; Volkenandt, M	1
Berd, D; Mastrangelo, MJ	1
McClay, EF; McClay, ME	1
Becker, JC; Bröcker, EB; Klingert, S; Winkler, B	1
Crowell, EB; Higa, GM	1
Appino, A; Bernengo, MG; Bertero, M; Colonna, S; Doveil, GC; Fierro, MT; Novelli, M	1
Chertoff, J; DelPrete, SA; Ernstoff, MS; Forcier, RJ; Lattanzi, SC; LeMarbre, PJ; Maurer, LH; Mott, L; O'Donnell, J; Tosteson, T	1
Armitage, GR; Bennett, K; Bodurtha, AJ; Burdette-Radoux, S; Iscoe, NA; James, KW; Jensen, J; Lohmann, RC; McCulloch, PB; Quirt, IC; Rusthoven, JJ; Silver, HK; Verma, S; Zee, B	1
Atzpodien, J; Kirchner, HH; Poliwoda, H	1
Ang, PT; Tan, EH	1
Fefer, A; Gold, PJ; Thompson, JA	1
Buzaid, AC; Poo, WJ; Schultz, MZ	1
Barón, AE; Bearman, SI; Bolwell, BJ; Cagnoni, PJ; Jones, RB; Mechling, BE; Overmoyer, BA; Purdy, MH; Ronk, B; Ross, M; Shpall, EJ; Taylor, CW	1
Byrd, DR; Fefer, A; Gold, PJ; Lindgren, CG; Markowitz, DR; Thompson, JA	1
Barth, NM; Dillman, RO; Honeycutt, PJ; Schulof, R; Soori, G; Stark, JJ; Wiemann, MC	1
A'Hern, RP; Atkinson, H; Constenla, DO; Dadian, G; Gore, ME; Johnston, SR; Moore, J; Riches, PG	1
Berd, D; Mastrangelo, MJ; McClay, EF	1
Atzpodien, J; Buer, J; Franzke, A; Ganser, A; Hoffmann, R; Kirchner, H; Lassmann, S; Müller, I; Neuber, K; Oevermann, K; Probst, M	1
Bernstein, Z; Drumea, K; Haim, N; Shklar, Z; Stein, ME; Steiner, M; Zalik, M	1
Bernard, EA; da Rocha, AB; Leyva, A; Logullo, AF; Mans, DR; Ruschel, C; Schwartsmann, G; Wetmore, LA	1
Creagan, ET; Dalton, RJ; Krook, JE; Long, HJ; Michalak, JC; Pitot, HC; Rowland, KM; Suman, VJ; Veeder, MH; Vukov, AM	1
Agarwala, SS; Begg, CB; Chapman, PB; Destro, AN; Einhorn, LH; Ernstoff, MS; Houghton, AN; Kirkwood, JM; Meyers, ML; Panageas, KS; Saxman, S; Schuchter, LM	1
Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N	1
Braybrooke, JP; Christodoulos, K; Ganesan, TS; Han, C; Harris, AL; Levitt, NC; O'Byrne, K; Propper, DJ; Talbot, DC	1
Cognetti, F; Sega, FM; Serrone, L; Zeuli, M	1
Ameri, A; Broët, P; Cornu, P; Delattre, JY; Keime-Guibert, F; Lafitte, C; Monjour, A; Napolitano, M	1
Eggermont, AM; Keilholz, U; Suciu, S	1
Church, C; DePriest, CB; Dillman, RO; Dobbs, TW; Ruben, RH; Schulof, R; Soori, G; Wiemann, MC	1
Aversa, SM; Cetto, GL; Chiarion Sileni, V; Corti, L; Favaretto, AG; Medici, M; Monfardini, S; Nortilli, R; Paccagnella, A	1
Atzpodien, J; Bröcker, EB; Fluck, M; Kamanabrou, D; Müller, I; Neuber, K; Neumann, C; Patzelt, T; Paul, E; Reitz, M; Rünger, TM; Schuler, G; von den Driesch, P	1
Bernstein, Z; Drumea, K; Haim, N; Sklar, Z; Stein, ME; Steiner, M; Tsalic, M	1
Li, Y; McClay, EF	1
Dmitruk, A; Kozlowski, L; Ostrowska, K; Wojtukiewicz, MZ; Zacharski, LR	1
Akimov, MA; Barchuk, AS; Gel'fond, ML; Gershanovich, ML	1
Calvet, D; Delattre, JY; Janoray, P; Rojas-Marcos, I	1
Eisen, TG; Lens, MB	1
Feun, L; Hurley, J; Marini, A; Mazumder, A; Moffat, F; Savaraj, N	1
Bearman, SI; Jones, RB; Nieto, Y; Shpall, EJ	1
Chang, JY; Kuo, CC; Liu, JF; Ma, LC; Shiah, HS	1
Lau, TK; Li, RH; Mok, TS; Ng, PC; Tam, B; Tam, WH	1
Bei, D; Meng, J; Youan, BB	1
Cheng, SJ; Kuo, YC	1

Reviews

7 review(s) available for carmustine and tamoxifen

Article	Year
Chemotherapy for advanced malignant melanoma. International journal of clinical & laboratory research, 1992, Volume: 21, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous	1992
Endocrine and cytostatic treatment of experimental mammary cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1980, Volume: 71 Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Carmustine; Castration; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Ergolines; Female; Fluorouracil; Mammary Neoplasms, Experimental; Methotrexate; Methylnitrosourea; Mice; Nitrosourea Compounds; Prednisolone; Rats; Tamoxifen; Vincristine	1980
Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Synergism; Humans; Melanoma; Tamoxifen; Treatment Outcome	1994
The Dartmouth Regimen: gone or going strong? Cancer investigation, 1998, Volume: 16, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Tamoxifen	1998
Systemic chemotherapy for the treatment of metastatic melanoma. Seminars in oncology, 2002, Volume: 29, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Paclitaxel; Tamoxifen; Taxoids; Temozolomide	2002
Systemic chemotherapy in the treatment of malignant melanoma. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Lomustine; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vincristine	2003
Engineering nanomedicines for improved melanoma therapy: progress and promises. Nanomedicine (London, England), 2010, Volume: 5, Issue:9 Topics: Antineoplastic Agents; Carmustine; Cisplatin; Dacarbazine; Drug Delivery Systems; Humans; Melanoma; Nanomedicine; Tamoxifen	2010

Trials

28 trial(s) available for carmustine and tamoxifen

Article	Year
Chemotherapy for advanced malignant melanoma. International journal of clinical & laboratory research, 1992, Volume: 21, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous	1992
Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma research, 1995, Volume: 5, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen	1995
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:6 Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infusions, Intravenous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Tamoxifen; Treatment Outcome	1995
Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma research, 1993, Volume: 3, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Soft Tissue Neoplasms; Tamoxifen	1993
Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma research, 1995, Volume: 5, Issue:5 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Sex Characteristics; Survival Rate; Tamoxifen	1995
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen	1996
[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a]. Medizinische Klinik (Munich, Germany : 1983), 1996, Apr-12, Volume: 91 Suppl 3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen	1996
Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma. Singapore medical journal, 1996, Volume: 37, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Singapore; Skin Neoplasms; Survival Rate; Tamoxifen	1996
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 4 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Tamoxifen; Treatment Outcome	1997
A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Melanoma research, 1997, Volume: 7, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Tamoxifen	1997
High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone marrow transplantation, 1997, Volume: 20, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Male; Middle Aged; Radionuclide Imaging; Recombinant Proteins; Tamoxifen; Transplantation, Autologous	1997
Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. The cancer journal from Scientific American, 1997, Volume: 3 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Prognosis; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Outcome	1997
Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program. Cancer, 1998, May-01, Volume: 82, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Recombinant Proteins; Tamoxifen	1998
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. British journal of cancer, 1998, Volume: 77, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Flow Cytometry; Humans; Interferon-alpha; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; T-Lymphocytes; Tamoxifen; Treatment Outcome	1998
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a. British journal of cancer, 1998, Volume: 78, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Risk; Survival Analysis; Tamoxifen; Treatment Outcome	1998
Sustained complete remission after chemobiohormonal therapy for metastatic melanoma. American journal of clinical oncology, 1999, Volume: 22, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Lung Neoplasms; Male; Melanoma; Middle Aged; Prospective Studies; Remission Induction; Skin Neoplasms; Tamoxifen	1999
Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Eye Neoplasms; Female; Humans; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Treatment Outcome	1999
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome	1999
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. British journal of cancer, 2000, Volume: 82, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome	2000
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. British journal of cancer, 2000, Volume: 82, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Tamoxifen	2000
Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study. Journal of neuro-oncology, 1999, Volume: 45, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Supratentorial Neoplasms; Survival Analysis; Tamoxifen; Thrombosis	1999
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11. Cancer biotherapy & radiopharmaceuticals, 2000, Volume: 15, Issue:5 Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Tamoxifen	2000
Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma research, 2001, Volume: 11, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Tamoxifen; Time Factors; Treatment Outcome	2001
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). British journal of cancer, 2002, Jan-21, Volume: 86, Issue:2 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Tamoxifen; Treatment Outcome	2002
Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study. American journal of clinical oncology, 2002, Volume: 25, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Tamoxifen	2002
Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial. Thrombosis and haemostasis, 2003, Volume: 89, Issue:2 Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Enoxaparin; Feasibility Studies; Glycosaminoglycans; Humans; Melanoma; Neoplasm Staging; Pilot Projects; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Tamoxifen; Treatment Outcome	2003
[Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma]. Voprosy onkologii, 2003, Volume: 49, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Extracellular Space; Female; Humans; Hyperthermia, Induced; Laser Coagulation; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome	2003
Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma. Cancer investigation, 2005, Volume: 23, Issue:1 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclosporine; Dacarbazine; Female; Humans; Immunosuppressive Agents; Interferon-alpha; Interleukin-2; Male; Melanoma; Skin Neoplasms; Tamoxifen; Treatment Outcome	2005

Other Studies

29 other study(ies) available for carmustine and tamoxifen

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Clinical trials referral resource. High priority trials--III. Breast cancer. Oncology (Williston Park, N.Y.), 1992, Volume: 6, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Intraductal, Noninfiltrating; Carmustine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Organoplatinum Compounds; Tamoxifen	1992
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Annals of plastic surgery, 1992, Volume: 28, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen	1992
Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Annals of plastic surgery, 1992, Volume: 28, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Survival Rate; Tamoxifen	1992
New approaches to the chemotherapy of melanoma. Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:5 Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine	1991
Malignant melanoma: primary presentation in bone marrow and lymph node. Medical and pediatric oncology, 1992, Volume: 20, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cisplatin; Dacarbazine; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Tamoxifen	1992
Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer, 1992, Jan-15, Volume: 69, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen	1992
Sequential chemoimmunotherapy for metastatic melanoma. Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen; Thrombocytopenia	1991
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer, 1989, Apr-01, Volume: 63, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombophlebitis	1989
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer treatment reports, 1987, Volume: 71, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Kidney Diseases; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombocytopenia; Thromboembolism; Vomiting	1987
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer treatment reports, 1984, Volume: 68, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Tamoxifen	1984
[Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer]. Onkologie, 1982, Volume: 5 Suppl Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carmustine; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Metastasis; Tamoxifen; Vinblastine; Vindesine	1982
Combination chemotherapy of metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Tamoxifen	1995
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer, 1994, Mar-15, Volume: 73, Issue:6 Topics: Adult; Aged; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Autoantibodies; Cardiolipins; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Immunoglobulin G; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Tamoxifen; Thromboembolism	1994
The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen. The West Virginia medical journal, 1993, Volume: 89, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Tamoxifen; Thrombophlebitis	1993
Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU. European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:5 Topics: Antineoplastic Agents; Carmustine; Cell Division; Drug Synergism; Etoposide; Gamma Rays; Glioblastoma; Humans; Immunohistochemistry; Protein Kinase C; Receptors, Estrogen; Tamoxifen; Transforming Growth Factor beta; Tumor Cells, Cultured	1999
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. Journal of experimental & clinical cancer research : CR, 2000, Volume: 19, Issue:1 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome	2000
What can we learn from phase II adjuvant trials in melanoma? British journal of cancer, 2000, Volume: 83, Issue:1 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Dacarbazine; Drug Synergism; Humans; Immunologic Factors; Interferons; Interleukin-2; Melanoma; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Research Design; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vinblastine	2000
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin. Neurology, 2003, Oct-14, Volume: 61, Issue:7 Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carboplatin; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Ependymoma; Gadolinium; Headache; Humans; Isotretinoin; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Remission Induction; Tamoxifen; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome	2003
Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy. American journal of clinical oncology, 2005, Volume: 28, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Mastectomy; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies; Risk; Survival Analysis; Tamoxifen; Transplantation Conditioning; Treatment Outcome	2005
Tamoxifen accelerates proteasomal degradation of O6-methylguanine DNA methyltransferase in human cancer cells. International journal of cancer, 2007, Nov-15, Volume: 121, Issue:10 Topics: Carmustine; Cell Line, Tumor; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Kinetics; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Proteasome Endopeptidase Complex; RNA, Messenger; Tamoxifen; Ubiquitin	2007
Microphthalmos associated with Dartmouth combination chemotherapy in pregnancy: a case report. The Journal of reproductive medicine, 2007, Volume: 52, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infant, Newborn; Liver Neoplasms; Male; Melanoma; Microphthalmos; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Skin Neoplasms; Tamoxifen	2007
Brain targeted delivery of carmustine using solid lipid nanoparticles modified with tamoxifen and lactoferrin for antitumor proliferation. International journal of pharmaceutics, 2016, Feb-29, Volume: 499, Issue:1-2 Topics: Antineoplastic Agents; Astrocytes; Blood-Brain Barrier; Brain; Carmustine; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Endothelial Cells; Fluoresceins; Glioblastoma; Humans; Lactoferrin; Lipids; Nanoparticles; Permeability; Tamoxifen	2016